Adjuvant Therapy for Stage III Melanoma Without Immediate Completion Lymph Node Dissection
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Adjuvant Therapy for Stage III Melanoma Without Immediate Completion Lymph Node Dissection
Authors
Keywords
-
Journal
ANNALS OF SURGICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-09-19
DOI
10.1245/s10434-021-10775-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era
- (2021) Devarati Mitra et al. ANNALS OF SURGICAL ONCOLOGY
- Active surveillance of patients who have sentinel node positive melanoma: An international, multi‐institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy trial II (MSLT‐2)
- (2021) Kristy Kummerow Broman et al. CANCER
- Use of Completion Lymph Node Dissection for Sentinel Lymph Node-Positive Melanoma
- (2020) Joshua N. Herb et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Adjuvant Therapy is Effective for Melanoma Patients with a Positive Sentinel Lymph Node Biopsy Who Forego Completion Lymphadenectomy
- (2020) Norma E. Farrow et al. ANNALS OF SURGICAL ONCOLOGY
- Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MLST-II: Multi-Institutional Propensity Score Matched Analysis
- (2020) Kristy K. Broman et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Current management of patients with melanoma who are found to be sentinel node‐positive
- (2019) Amanda A. G. Nijhuis et al. ANZ JOURNAL OF SURGERY
- The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care
- (2018) Emily Z. Keung et al. Expert Review of Anticancer Therapy
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
- (2017) Mark B. Faries et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
- (2017) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- SPECT/CT Improves Detection of Metastatic Sentinel Lymph Nodes in Patients with Head and Neck Melanoma
- (2016) Brandon C. Chapman et al. ANNALS OF SURGICAL ONCOLOGY
- Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial
- (2016) Ulrike Leiter et al. LANCET ONCOLOGY
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma
- (2014) Donald L. Morton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sentinel Node Tumor Burden According to the Rotterdam Criteria Is the Most Important Prognostic Factor for Survival in Melanoma Patients
- (2008) Alexander C. J. van Akkooi et al. ANNALS OF SURGERY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started